BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...have any bispecifics of its own in the clinic, it has an option to acquire TNB-383B...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

...Online Intelligence, ClinicalTrials.gov Meredith Durkin Wolfe, Associate Editor, Data & Analytics belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) orva-cel (JCARH125) CAR-BCMA, CT053 HPN217 P-BCMA-101 PBCAR269A REGN5458 SEA-BCMA ALLO-715 TNB-383B MEDI2228 AMG...
BioCentury | Feb 13, 2019
Company News

AbbVie gains option to Teneobio BCMA program

...TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset. TNB-383B...
...and is in preclinical testing to treat multiple myeloma. CBO Omid Vafa told BioCentury that TNB-383B...
...binder to decouple target cancer cell killing from cytokine release. Vafa said the company believes TNB-383B...
BioCentury | Feb 11, 2019
Company News

AbbVie gains option to Teneobio BCMA program

...TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset. TNB-383B...
...and is in preclinical testing to treat multiple myeloma. CBO Omid Vafa told BioCentury that TNB-383B...
...binder to decouple target cancer cell killing from cytokine release. Vafa said the company believes TNB-383B...
Items per page:
1 - 4 of 4